Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) Equity Average (2020 - 2025)

Historic Equity Average for Journey Medical (DERM) over the last 6 years, with Q3 2025 value amounting to $22.6 million.

  • Journey Medical's Equity Average rose 10315.92% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 10315.92%. This contributed to the annual value of $20.2 million for FY2024, which is 826.9% up from last year.
  • According to the latest figures from Q3 2025, Journey Medical's Equity Average is $22.6 million, which was up 10315.92% from $20.4 million recorded in Q2 2025.
  • Journey Medical's Equity Average's 5-year high stood at $41.7 million during Q1 2022, with a 5-year trough of $3.7 million in Q2 2023.
  • In the last 5 years, Journey Medical's Equity Average had a median value of $17.8 million in 2023 and averaged $19.4 million.
  • As far as peak fluctuations go, Journey Medical's Equity Average crashed by 9016.57% in 2023, and later soared by 22340.94% in 2024.
  • Quarter analysis of 5 years shows Journey Medical's Equity Average stood at $15.2 million in 2021, then soared by 42.3% to $21.6 million in 2022, then fell by 12.61% to $18.9 million in 2023, then fell by 17.84% to $15.5 million in 2024, then skyrocketed by 45.65% to $22.6 million in 2025.
  • Its Equity Average stands at $22.6 million for Q3 2025, versus $20.4 million for Q2 2025 and $20.8 million for Q1 2025.